Investor Update November 2026 Understanding the Path Forward IN THIS ISSUE A Message from CEO Marc Voigt ............................................................................................... 2 Recent Highlights...
Immutep Investor Update
Filed with ASX · · 11 pages · English
Release
Story so far
Earlier from Immutep
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
- Immutep Expands US Patents for Efti Combination Therapies
- EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
- IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition
Later from Immutep
All Immutep news releasesFollow Immutep into a list and get an email when it puts out news.
Follow Immutep